David E. Wheadon - 20 Oct 2022 Form 4 Insider Report for ChemoCentryx, Inc.

Role: Director
Signature: /s/ Susan M. Kanaya, as Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 20 Oct 2022
Net transaction value: $0
Form type: 4
Filing time: 24 Oct 2022, 18:58:04 UTC
Previous filing: 08 Aug 2022
Next filing: 31 May 2023
SEC filing: View on sec.gov

Key filing fact

David E. Wheadon filed Form 4 for ChemoCentryx, Inc. on 24 Oct 2022.

Key facts

This page summarizes David E. Wheadon's Form 4 filing for ChemoCentryx, Inc..
1 reported transaction and 1 derivative row are listed below.
Filing timestamp: 24 Oct 2022, 18:58.

Change

Previous filing in this sequence was filed on 08 Aug 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

See Original Filing

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

CCXI transaction Derivative

Restricted Stock Unit

Disposed to Issuer

Transaction value
Shares: -22,274
Change %: -100%
Price
Shares after: 0
Date: 20 Oct 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 22,274
Exercise price
Footnotes: F1, F2

An asterisk next to the price means the reported price is likely invalid.

David E. Wheadon is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id	Content
F1	Reflects the disposition of securities pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 3, 2022, among Amgen Inc. ("Parent"), Carnation Merger Sub, Inc. ("Merger Sub") and ChemoCentryx, Inc. (the "Company"), pursuant to which, on October 20, 2022, Merger Sub merged with and into the Company, with the Company surviving the merger as a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger (the "Effective Time"), each restricted stock unit of the Company held by the Reporting Person that was outstanding immediately prior to the Effective Time and that was (A) granted prior to August 3, 2022 or granted after August 3, 2022 and specified in the disclosure schedules delivered by the Company to Parent in connection with the Merger Agreement and/or (B) granted to a non-employee member of the board of directors of the Company became fully vested and was cancelled and converted into the right to receive an amount in cash,
F2	(Continued from Footnote 1) less applicable withholding taxes and without interest, equal to (x) the total number of shares of common stock, par value $0.001 per share, of the Company underlying such restricted stock unit multiplied by (y) $52.00. The restricted stock units did not have an expiration date.

Content

Reflects the disposition of securities pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 3, 2022, among Amgen Inc. ("Parent"), Carnation Merger Sub, Inc. ("Merger Sub") and ChemoCentryx, Inc. (the "Company"), pursuant to which, on October 20, 2022, Merger Sub merged with and into the Company, with the Company surviving the merger as a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger (the "Effective Time"), each restricted stock unit of the Company held by the Reporting Person that was outstanding immediately prior to the Effective Time and that was (A) granted prior to August 3, 2022 or granted after August 3, 2022 and specified in the disclosure schedules delivered by the Company to Parent in connection with the Merger Agreement and/or (B) granted to a non-employee member of the board of directors of the Company became fully vested and was cancelled and converted into the right to receive an amount in cash,

(Continued from Footnote 1) less applicable withholding taxes and without interest, equal to (x) the total number of shares of common stock, par value $0.001 per share, of the Company underlying such restricted stock unit multiplied by (y) $52.00. The restricted stock units did not have an expiration date.